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Certain mitochondrial haplotypes (mthaps) are associated with disease, possibly through differences in
oxidative phosphorylation and/or immunosurveillance. We explored whether mthaps are associated with
allogeneic hematopoietic cell transplantation (HCT) outcomes. Recipient (n ¼ 437) and donor (n ¼ 327) DNA
were genotyped for common European mthaps (H, J, U, T, Z, K, V, X, I, W, and K2). HCT outcomes for mthap
matched siblings (n ¼ 198), all recipients, and all donors were modeled using relative risks (RR) and 95%
conﬁdence intervals and compared with mthap H, the most common mitochondrial haplotypes. Siblings with
I and V were signiﬁcantly more likely to die within 5 years (RR ¼ 3.0; 95% conﬁdence interval [CI], 1.2 to 7.9;
and RR ¼ 4.6; 95% CI, 1.8 to 12.3, respectively). W siblings experienced higher acute graft-versus-host disease
(GVHD) grades II to IV events (RR ¼ 2.1; 95% CI, 1.1 to 2.4) with no events for those with K or K2. Similar
results were observed for all recipients combined, although J recipients experienced lower GVHD and higher
relapse. Patients with I donors had a 2.7-fold (1.2 to 6.2) increased risk of death in 5 years, whereas few
patients with K2 or W donors died. No patients with K2 donors and few patients with U donors relapsed.
Mthap may be an important consideration in HCT outcomes, although validation and functional studies are
needed. If conﬁrmed, it may be feasible to select donors based on mthap to increase positive or decrease
negative outcomes.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Mitochondria (mt) are essential organelles of bacterial
origin captured by eukaryotic cells through endosymbiosis
billions of years ago (reviewed in [1]). Mt provide energy to
cells through oxidative phosphorylation (OXPHOS) and
electron transport, regulate cell survival and death, and are
increasingly thought to play a key role in innate and adaptive
immune system responses [2-4]. Although most mitochon-
drial DNA (mtDNA) was incorporated into human nuclear
DNA throughout evolution, there remains a 16.6 kb closed
double-stranded circular mitochondrial genome thatdgments on page 87.
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ty for Blood and Marrow Transplantation.contains 37 genes encoding 22 tRNAs, 2 rRNAs, and 13 pro-
teins that play an integral role in OXPHOS [5,6]. Unlike nu-
clear DNA, which is inherited from both maternal and
paternal sources, paternal mtDNA is degraded by ubiquiti-
nation during fertilization; thus, mtDNA inheritance is
almost exclusively maternal.
Like nuclear DNA, mtDNA can experience deletions and
mutations that lead to a variety of rare diseases, including
dystonia, myopathies, myoclonic epilepsy and ragged red
ﬁbers, lactic acidosis, Leber’s hereditary optic neuropathy,
aminoglycoside-induced sensorineuronal hearing loss, and
Pearson’s syndrome, among others [1,7-9]. In contrast to
nuclear DNA, the mt genome can accumulate mutations
much more readily because it contains no introns or his-
tones; thus, mtDNA heteroplasmy is often seen with aging
and may also contribute to disease risk or modify disease
severity [9-11].
Table 1
Patient (n ¼ 437) Demographics Across Entire Study Population
Variable Total Study Group
Patient age, yr
0-17 83 (19.0%)
18 354 (81.0%)
Yr of transplantation
1995-2000 166 (38.0%)
2000-2005 271 (62.0%)
Patient sex
Male 250 (57.2%)
Female 187 (42.8%)
Patient race
Caucasian 376 (86.0%)
Hispanic 16 (3.7%)
Asian 14 (3.2%)
Unknown 12 (2.7%)
Mixed 9 (2.1%)
African American 7 (1.6%)
American Indian 3 (.7%)
Donor type
Sibling 198 (45.3%)
URD 73 (16.7%)
Single UCB 44 (10.1%)
Double UCB 107 (24.5%)
Related other 15 (3.4%)
Conditioning
Myeloablative 302 (69.1%)
RIC 135 (30.9%)
Recipient CMV serostatus
Rþ 219 (50.1%)
R/D 177 (40.5%)
R/Dþ 41 (9.4%)
Conditioning
Cy/TBI  ATG 418 (95.7%)
Bu/Cy/Melphalan 2 (0.5%)
Bu/Flu/TBI 10 (2.3%)
Cy/TBI/VP16 1 (0.2%)
GVHD prophylaxis
CNI þ MTX 225 (51.5%)
CsA/MMF 182 (41.6%)
CsA  MPD  ATG 27 (6.2%)
CsA/MTX/Pred 2 (0.5%)
Diagnosis
AML 122 (27.9%)
NHL 81 (18.5%)
ALL 78 (17.8%)
CML 64 (14.6%)
MDS/MPS 40 (9.2%)
Hodgkins 23 (5.3%)
CLL 13 (3.0%)
JMML 8 (1.8%)
Other malignancy 8 (1.8%)
Disease risk
Std risk 227 (51.9%)
High risk 210 (48.1%)
RIC indicates reduced-intensity conditioning; R, recipient; D, donor; Cy,
cyclophosphamide; TBI, total body irradiation; ATG, antithymocyte glob-
ulin; Bu, busulfan; Flu, ﬂudarabine; VP16, etoposide, CNI, calcineurin in-
hibitor; MTX, methotrexate; CsA, cyclosporin A; MMF, mycophenolate
mofetil; MPD, methylprednisolone; Pred, predinsolone; AML, acute myeloid
leukemia; NHL, non-Hodgkin lymphoma; ALL, acute lymphoblastic leuke-
mia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome;
MPS, myeloproliferative syndrome; CLL, chronic lymphoid leukemia; JMML,
juvenile myelomonocytic leukemia; std, standard.
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line, and it is a useful marker of humanmigration around the
globe [12]. Approximately 30 mt haplotypes (mthaps) have
been identiﬁed by restriction fragment length polymorphism
worldwide [13,14], with additional subdivisions among
haplotype groups. Select mthaps are found in indigenous
populations within speciﬁc regions of the world, suggesting
either climatic selection or genetic drift [15]. Haplotype L is
the oldest, with origins in Africa, and it gave rise to macro-
haplogroups (M, N, R) in Europe and Asia and subsequent
descendant sublineage haplotypes (www.mitomap.org).
Haplotype H is the most common in Western Europe.
Nevertheless, within any 1 self-identiﬁed race/ethnicity
group or geographic region, population admixture can be
variable, making it sometimes difﬁcult to strongly associate
race or ethnicity with speciﬁc mthaps [16].
Using cytoplasmic hybrids (cybrids), which are cells
consisting of identical nuclear DNA but containing different
mt haplotypes, there is increasing evidence of OXPHOS,
reactive oxygen species (ROS), and other functional differ-
ences among mthaps [17,18], supporting a role for these
polymorphisms in cell function and/or disease susceptibility.
Related, several association studies have linked mthaps with
longevity [19], speciﬁc cancers [20], Leber’s hereditary optic
neuropathy [21], survival after sepsis [22], progression to
heart disease [23], and progression from human immuno-
deﬁciency virus to acquired immunodeﬁciency syndrome
[24], whereas others have found no associations [25,26].
Although differences between donor and recipient mtDNA
have been used to quantitate donor engraftment after allo-
geneic transplantation [27], no study to our knowledge has
investigated mthaps in relation to hematopoietic cell trans-
plantation (HCT) outcomes.
Allogeneic HCT is a time of high metabolic demand: there
is a need for hematopoietic restoration and response to
febrile and septic events, as well as response to challenges of
graft-versus-host disease (GVHD) and graft-versus-leukemia
reactions [28]. Given increasing evidence of functional dif-
ferences in mthap cellular energetics [2-4,23], mthap varia-
tions could be important in HCT outcomes. We explored
associations between mthaps of recipients and donors on
patient outcomes after HCT. Our data suggest that certain
mthaps may be important independent predictors of mor-
tality, GVHD, and relapse.
METHODS
Patient Demographics
Pretransplantation DNA was available from 437 adult and pediatric
patients who received an allogeneic HCT at the University of Minnesota for a
hematological malignancy between 1995 and 2005, along with DNA from
327 donors (DNA was not available from 110 umbilical cord blood [UCB]
donors). Of the transplantations, 213 were related donor (198 siblings, 15
other related), 73 adult unrelated, and 151 UCB (Table 1). Clinical and lab-
oratory data were systematically and prospectively collected on all patients
and entered into the University of Minnesota Blood and Marrow Transplant
Database. All patients and/or their parents or guardians provided signed
consent to participate in institutional review boardeapproved trans-
plantation protocols; outcomes were reviewed retrospectively.
Mthap DNA Testing
Participants were assessed for the 11 most common European mthaps
(in descending order of frequency: H, J, U, T, Z, K, V, X, I, W, and K2), which
required genotyping each DNA sample for 8 different mt single nucleotide
polymorphisms (SNPs), including mt1719, mt4580, mt7028, mt8251,
mt9055, mt10398, mt12308, and mt13368 using Taqman [29]. For each
Taqman SNP assay performed, a master mix was made using 1X concen-
tration of Taqman 2X genotyping master mix (Life Technologies, Grand Is-
land, NY), 5 mM of each forward and reverse primer and 1 mM of each 4,7,2’-
trichloro-7’-phenyl-6-carboxyﬂuorescein (VIC) and 6-carboxyﬂuorescein(FAM) probe (Life Technologies, Grand Island, NY) aliquoted to a ﬁnal vol-
ume of 11.5 mL per well in a 96-well plate. Using a multichannel pipette, 1 mL
of DNA (average concentration, 2.5 ng/mL) was pipetted from stock DNA into
the assay plate for a ﬁnal volume reaction of 12.5 mL. Each plate included 4
negative controls, 4 positive controls for the VIC-labeled allele, 4 positive
control wells for the FAM labeled allele, and 5% duplicates to verify calls.
After plating was complete, an adhesive cover was securely applied and the
plate was placed in a thermal cycler for the following: 2 minutes at 50C
followed by 10 minutes at 95C, then 40 cycles of 15 seconds at 95C fol-
lowed by 1 minute at 60C. After cycling, the plate was read on a 7900HT
Prism Sequence Detection System (Life Technologies, Grand Island, NY)
Table 2
Mitochondrial Haplotype (mthap) Frequencies for Recipients and Donors
mthap (Recipient)
H 156 (35.7%)
I 7 (1.6%)
J 59 (13.5%)
K 22 (5.0%)
K2 7 (1.6%)
T 39 (8.9%)
U 55 (12.6%)
V 16 (3.7%)
W 7 (1.6%)
X 15 (3.5%)
Z 35 (8.0%)
Other 19 (4.3%)
mthap (Donor)
H 127 (37.6%)
I 7 (2.1%)
J 36 (11.0%)
K 18 (5.5%)
K2 7 (2.1%)
T 32 (9.8%)
U 34 (9.2%)
V 9 (2.8%)
W 4 (1.2%)
X 8 (2.4%)
Z 35 (10.7%)
Other 10 (3.1%)
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Detection Software v.2.1.1 (Applied Biosystems/Life Technologies, Grand Is-
land, NY). This procedure was performed for all 8 SNPs separately. After an
allele call for all 8 SNPs for a single sample, 1 of the 11 mthaps was deter-
mined using a checkerboard approach [29]. A total of 29 samples (19 patient,
10 donor) had an mthap that did not correspond to 1 of the 11 European
groups deﬁned by the above primer sets and were labeled as “other.”
Transplantation Regimens, GVHD Prophylaxis, and Data Collection
Data on characteristics of transplantation, post-transplantation com-
plications, and outcomes were prospectively collected by the Biostatistical
Support Group at the University of Minnesota using standardized collection
procedures. Details regarding graft selection, conditioning regimens, and
GVHD prophylaxis have been previously described [30-34]. All patients were
followed longitudinally until death or last follow-up. Endpoints considered
included disease-free survival (DFS) through 5 years, nonrelapse mortality
(NRM), relapse, and GVHD.
Statistical Analysis
The analysis focused on the inﬂuence of mthap on HCT outcomes in
matched siblings, all recipients (including matched sibling patients, other
related donor patients, and patients with unrelated donors [URD] and UBC
HCTs), and all donors (including matched sibling donors, other related do-
nors, URDs and UBCs) with available DNA. The “all recipient” and “all donor”
groups were strongly inﬂuenced by the dominant sibling group, as, unfor-
tunately, we had insufﬁcient sample size to evaluate URD or UCB donors
separately from the siblings.
Comparisons between donor sources were completed by the general
Wilcoxon test for continuous factors and the chi-square test for categorical
factors. Factors considered for adjustment included stem cell source
(marrow versus peripheral blood), age (<18 versus 18 years), disease risk
(standard versus high), conditioning (reduced-intensity conditioning versus
myeloablative), recipient cytomegalovirus [CMV] serostatus (positive versus
negative), and patient sex. Disease risk at the time of HCT was classiﬁed into
standard risk or high risk, based on the American Society for Blood and
Marrow Transplantation Request for Information (ASBMT RFI) 2006 risk
scoring schema (http://www.asbmt.org). Acute leukemia in ﬁrst or second
complete remission, chronic myeloid leukemia in ﬁrst chronic phase,
Hodgkin’s or non-Hodgkin’s lymphoma in complete or partial
chemotherapy-sensitive remission, chronic lymphoblastic leukemia in ﬁrst
remission, myelodysplastic syndrome, and myeloproliferative disorder
without excess blasts were considered standard risk; all others were
considered high risk at the time of transplantation. Association between
HLA and haplotypes was assessed by Fisher’s exact test. DFS was estimated
by Kaplan-Meier curves [35]. NRMwas analyzed using cumulative incidence
treating relapse as a competing risk. Relapse and GVHDwere analyzed using
cumulative incidence treating nonevent death as a competing risk [36].
Comparisons were completed with the simple log-rank test. Cox regression
was used to assess the independent effect of the indices on 5-year overall
DFS [37] and Fine and Gray proportional hazards regression was used to
assess the independent effect of the indices on NRM, relapse, and GVHD
[38]. The most common mthap, H, was used as the referent group. Forest
plots were used to facilitate visualization.
RESULTS
Mthap data were available from pretransplantation
specimens collected from 437 patients and 327 donors.
Table 1 shows patient demographic data among the entire
study population. Over 80% of patients were 18 years or older
at transplantation (range, 6 months to 69.6 years; median,
39.9 years). The majority (45%) of transplantations were
matched related siblings, followed by double UBC (24.5%)
and URD transplantations (16.7%). Overall, the distribution of
mthaps in both patients and donors was comparable
(Table 2), with H being the most frequent. Below we present
transplantation outcomes based on mthap of siblings, all
recipients, and all donors, with the latter 2 groups combining
matched related donors and URD.
Sibling HCT Outcomes
All 198 sibling donors matched their recipients on mthap,
as expected, given they have the same biological mother. The
majority of sibling recipients received myeloablative condi-
tioning for a variety of malignant hematological diseases
(data not shown). Most (73%) received peripheral blood stemcells; GVHD prophylaxis was mainly with cyclosporine/
methotrexate (75%). MtHap did not signiﬁcantly differ by
patient age, year of transplantation, sex, donor type, CMV
serostatus, conditioning regimen, GVHD prophylaxis, disease
risk, HLA mismatch, or source of cells (data not shown).
Eighty-nine percent of patients across the European mthaps
self-identiﬁed as non-Hispanic white (NHW), with the ex-
ceptions of Z (n ¼ 15; 53% NHW, 20% Hispanic, 20% Asian, 7%
mixed), V (n¼ 5; 60% NHW, 40% unknown), and K (n¼ 8, 75%
NHW, 13% mixed, 13% unknown).
A total of 109 of 198 (55%) sibling recipients died within 5
years of transplantation, but there were signiﬁcant differ-
ences depending on mthap. Compared with those with
haplotype H (43 events/83 patients, 52%), recipients with I
and V were signiﬁcantly more likely to die within 5 years
from HCT (n ¼ 5 of 6 [83%], risk ratio [RR] ¼ 3.0; 95% conﬁ-
dence interval [CI], 1.2 to 7.9; n¼ 5 of 5 [100%]; RR¼ 4.6; 95%
CI, 1.8 to 12.3; respectively), after controlling for stem cell
source, age, disease risk, conditioning, CMV status, and sex
(Figure 1). A total of 55 of 198 (28%) sibling recipients died of
NRM events in 2 years. Compared with patients with H (21 of
83, 26%), 80% of patients with V experienced NRM within 2
years after transplantation (RR ¼ 5.1; 95% CI, 1.9 to 13.7),
whereas no patients withW (n¼ 4) or “other” (n¼ 8) died in
that time period. Overall, 48 of 198 (25%) sibling recipients
relapsed within 5 years of transplantation (Figure 1). There
were no statistically signiﬁcant differences among mthap
compared with those with H (24% had events).
Seventy-ﬁve (38%) patients experienced grade II to IV
acute GVHD (aGVHD) within 100 days of transplantation
(data not shown). Compared with those with H (39% total
events), however, there were signiﬁcantly higher events
among thosewithW (3 of 4 [75%]; RR¼ 2.1; 95% CI,1.1 to 4.2)
and those in the “other” group (6 of 8 [75%]; RR¼ 4.3; 95% CI,
1.5 to 11.7). Twenty-four (12%) patients experienced grades
III and IV aGVHD by day 100. Compared with those with H (9
of 83, 11%), patients with U (5 of 19, 26%) and with V (2 of 5,
40%) experienced signiﬁcantly higher events (RR ¼ 3.1; 95%
CI, 1.0 to 9.3; and RR ¼ 4.4; 95% CI, 1.1 to 17.7; respectively);
there were no events for those with K, K2, or X.
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Figure 1. Multivariate analysis of transplantation outcomes for mthap-matched sibling donors and recipients based on European mthaps. All outcomes were
normalized to mthap H, which was the most common. Outcomes are shown for DFS (relative risk [RR] reﬂects risk of death), NRM, relapse, and GVHD. Factors that we
attempted to adjust for included stem cell source (marrow versus peripheral blood stem cells), age (<18 versus 18), disease risk (standard versus high), conditioning
(reduced-intensity conditioning versus myeloablative), recipient CMV serostatus (positive versus negative) and patient sex (male versus female). Dashed lines
represent signiﬁcance at the P < .05 level.
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GVHD (cGVHD). However, after controlling for the competing
risk of non-GVHD death within 2 years, there were no
mthaps that were signiﬁcantly different than those of people
with H.
All Recipients Combined and HCT Outcomes
As the above comparison within siblings could not
distinguish whether recipient or donor mtDNA played
differing roles in outcomes, we combined the sibling cohort
with the remaining group of transplantations, which added
239 recipients (15 nonsibling related donor, 73 adult URD,
and 151 UCB donors).
Of the 437 recipients, 241 (55%) died within 5 years of
transplantation (data not shown). Compared with those with
haplotype H with 89 of 156 events (57%), recipients with I
were more likely to die in 5 years (n ¼ 6 of 7 [86%]; RR ¼ 2.4;
95% CI,1.0 to 5.4), whereas in contrast to the 198matched full
siblings, individuals in the recipients overall group having
mthap V did not experience a signiﬁcantly increased risk of
death (12 of 16 [75%]; RR ¼ 1.4; 95% CI, .8 to 2.6) after con-
trolling for donor type, age, disease risk, conditioning, CMV
status, and sex (Figure 2). Overall, 118 of 437 (27%) patients
experienced NRM in 2 years. Compared with those with H
(31%), recipients with W (n ¼ 7) experienced no events
(P ¼ .10).Relapse occurred in 115 of 437 patients within 5 years of
transplantation (data not shown). There were no signiﬁcant
differences among mthaps compared with those with H (37
of 156 events [24%]), although no patients with K2 (n ¼ 7)
experienced relapse (Figure 2).
A total of 195 (45%) patients experienced grade II to IV
aGVHD within 100 days of transplantation (data not
shown). Compared with those with H (78 of 156 [50%]
events), recipients with J and K experienced signiﬁcantly
fewer events (17 of 59 [29%], RR ¼ .50; 95% CI, .3 to .8; and
6 of 22 [27%]; RR ¼ .4; 95% CI, .2 to .9; respectively)
(Figure 2). Seventy-one (16%) patients experienced grade III
to IV aGVHD by day 100. Compared with those with H (30
of 156, 19%), patients with J (5 of 59, 8%) experienced fewer
events (RR ¼ .4; 95% CI, .1 to 1.0), whereas no patients with
K2 (n ¼ 7) or X (n ¼ 15) experienced grade III and IV
aGVHD. In contrast to the matched siblings, recipients
overall with U (30 of 50, 55%) and V (12 of 16, 75%)
experienced more events compared with H (89 of 156,
57%), but they did not reach statistical signiﬁcance
(Figure 2).
A total of 139 (32%) patients experienced cGVHD. After
controlling for the competing risk of non-GVHD death
within 2 years, there were no recipient haplotypes
that were signiﬁcantly different than mthap H (59 of
156, 38%).
DFS
M
T 
H
ap
lo
ty
pe
I
J
K
K2
T
other
U
V
W
X
Z
0.2 0.5 1 2 5
NRM
I
J
K
K2
T
other
U
V
W
X
Z
0.2 0.5 1 2
Relapse
M
T 
H
ap
lo
ty
pe
I
J
K
K2
T
other
U
V
W
X
Z
0.5 1 2 5 10
II-IV AGvHD
I
J
K
K2
T
other
U
V
W
X
Z
0.1 0.2 0.5 1 2
III-IV AGvHD
M
T 
H
ap
lo
ty
pe
I
J
K
K2
T
other
U
V
W
X
Z
0.1 0.2 0.5 1 2 5
RR
RR
RR
RR
RR
Figure 2. Multivariate analysis of transplantation outcomes for all recipients based on European mthaps. All outcomes were normalized to mthap H, which was the
most common. Outcomes are shown for DFS (relative risk [RR] reﬂects risk of death), NRM, relapse, and GVHD. Factors that we attempted to adjust for included donor
type (HLA sibling match versus sibling mmþURD versus UCB), age (0 to 18 versus 18þ), disease risk (standard versus high), conditioning (reduced-intensity con-
ditioning versus myeloablative), recipient CMV serostatus (positive versus negative) and patient sex (male versus female). Dashed lines represent signiﬁcance at the
P < .05 level.
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Finally, we combined the 198 sibling donors with the
remaining group of 129 donors with DNA available. Of the
327 recipients with known donor mthap, 176 (54%) died
within 5 years of transplantation. Compared with H donors
(68 of 127, 54%), patients who received transplants from I
donors (6 of 7, 86%) were 2.7 times (95% CI, 1.2 to 6.2) more
likely to die after controlling for donor type, age disease risk,
CMV status, and sex (Figure 3); V donors were also associated
with higher risk of death in recipients (8 of 9, 89%; RR ¼ 2.1;
95% CI, 1.0 to 4.5). Overall, 97 (30%) patients experienced
NRM in 2 years (data not shown). There were no statistically
signiﬁcant differences for any of the mthaps; however, there
was no NRM among recipients from W (n ¼ 4) or “other”
(n ¼ 10) donors (Figure 3).
Overall, 70 of 327 (21%) patients relapsed within 5 years
of transplantation. Although there were no signiﬁcant dif-
ferences among haplotype groups compared with H donors
(27 of 127, 23%), no patients receiving transplants from K2
donors (n ¼ 7) experienced relapse. Further, patients who
received transplants from J donors experienced a 49%reduction in relapse (95% CI, .2 to 1.5), with only 4 of 36 (11%)
events (Figure 3).
A total of 127 (39%) patients experienced grade II to IV
aGVHD within 100 days of transplantation. There were
signiﬁcantly higher events among the “other” donor group
(7 of 10, 70%; RR ¼ 2.7; 95% CI, 1.0 to 6.8), and borderline
signiﬁcantly higher events among recipients of W donors
(3 of 4, 75%; RR ¼ 2.3; 95% CI, 1.0 to 5.4) (Figure 3) compared
with H donors (48 of 127, 38%). For grade III to IV aGVHD,
compared with H donors (16 of 127, 13%), patients who
received transplants fromU donors experienced signiﬁcantly
higher events (10 of 34, 29%; RR ¼ 2.3; 95% CI, 1.1 to 4.9),
whereas patients receiving transplants from donors with
haplotype X and K experienced few events (0 of 8 and 1 of 18,
respectively).
Last, a total of 107 (33%) patients experienced cGVHD.
After controlling for the competing risk of non-GVHD death
within 2 years (the majority of patients who received
transplants from donors with haplotype V and I died), there
were no haplotype donors that were associated with signif-
icantly different outcomes from H donors (48 of 127, 38%).
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Figure 3. Multivariate analysis of transplantation outcomes based on donor European mthaps. All outcomes were normalized to mthap H, which was the most
common. Outcomes are shown for DFS (relative risk [RR] reﬂects risk of death), NRM, relapse and GVHD. Factors that we attempted to adjust for included donor type
(HLA sibling match versus sibling mmþURD versus UCB), age (0 to 18 versus 18þ), disease risk (standard versus high), conditioning (reduced-intensity conditioning
versus myeloablative), recipient CMV serostatus (positive versus negative) and patient sex (male versus female). Dashed lines represent signiﬁcance at the P < .05
level.
J.A. Ross et al. / Biol Blood Marrow Transplant 21 (2015) 81e8886DISCUSSION
To our knowledge, this is the ﬁrst study to explore asso-
ciations between patient and donor mthaps and HCT out-
comes. We ﬁrst focused on biological siblings, given they
were themost homogenous group with respect to mtDNA, as
they were all matched. We found that compared with
haplotype H (see Supplemental Table 1), there were signiﬁ-
cantly increased risks of (1) death at 5 years from HCT for
mthaps I and V; (2) NRM for V; (3) aGVHD II to IV for W and
the “other” group; and (4) aGVHD III to IV for U and V. In
contrast, we observed lower risks of (1) death 5 years from
HCT for K2 and W; (2) NRM for W; (3) relapse for K2; (4)
aGVHD II to IV for J, K, and K2; and (5) aGVHD III to IV for K,
K2, and X. However, because siblings are matched on mthap,
it was impossible to distinguish the contribution of recipient
or donor mthaps to these HCT outcomes, and, unfortunately,
we had insufﬁcient sample size to evaluate other recipient
and donor groups separately from siblings. Thus, to evaluate
which mthap (donor or recipient) might be driving sibling
associations, we combined the other related, adult URD, and
UCB recipients and donors with the siblings to determine
whether the associations in the matched siblings became
stronger or weaker or if new associations emerged.For 5-year overall survival, similar to siblings, mthap I was
associated with a signiﬁcantly increased risk of death over
mthap H for all recipients and all donors (Supplemental
Table 1). However, donors with mthap V were associated
with an increased risk of patient death, but recipients with V
had no increased risk, suggesting V donors may be contrib-
uting to the increased risk of death in siblings. Similar to
siblings, recipients or donors with K2 or W were associated
with fewer deaths, albeit with very small numbers of pa-
tients in each group. For 2-year NRM, again V donors rather
than V recipients appeared to be driving the signiﬁcant as-
sociation in siblings. Identical to siblings, recipients or do-
nors with mthap W were associated with no patient NRM
events. For 5-year relapse, J recipients experienced border-
line signiﬁcantly higher events compared with H, which was
not observed in either the sibling or donor groups. Identical
to siblings, K2 donors and patients with K2 recipients
experienced no relapse. For aGVHD II to IV, W donors
appeared to be contributing to the signiﬁcantly increased
risk in siblings, whereas J recipients experienced a signiﬁ-
cantly lower number of events that was not observed with
the J donor group. Similar to siblings, patients with K or K2
mthaps or receiving HCT from K or K2 donors, experienced
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IV, U donors appeared to be driving the signiﬁcantly
increased risk in matched siblings, whereas V was only
signiﬁcantly associated with an increased risk in the siblings.
J recipients experienced signiﬁcantly fewer aGVHD III to IV
events, which were not observed in siblings or donors. K, K2,
and X experienced few aGVHD III to IV events regardless of
donor or recipient status.
MtDNA lacks introns; thus, genetic variation can lead to
amino acid substitutions and functional changes in the pro-
teins they encode, resulting in variation in OXPHOS, ROS
production, or other essential mitochondrial functions
[39,40]. Although the function of many of the 11 European
mthaps remains to be determined, cybrid studies show
notable differences in oxygen consumption (higher in H
compared with J [41]), susceptibility to ROS (higher in H
compared to T [18] or J [42]), mt copy number (higher in J
compared with H [43]), and adenosine triphosphate (ATP)
production (lower in J compared with H [42]). As functional
studies of mthaps in donors and recipients have not yet been
done in the context of HCT, we can only speculate on un-
derlying mechanisms for our observations.
For recipients, mthaps could inﬂuence the cellular
energetics needed for tissue repair after chemotherapy
and radiation, and thus contribute to increased mortality,
aGVHD and/or relapse. In our study, we observed signiﬁ-
cantly lower risks of GVHD but higher risk of relapse in J
recipients compared with H recipients. Mthap J is associated
with lower OXPHOS and ATP production [41,42]; it is possible
that such a response in recipients could contribute to a lower
GVHD response, which has been associated with higher
relapse [44].
For donors, mthaps could also inﬂuence cellular ener-
getics [45] and/or the relative magnitude and duration of an
alloreactive response. Recent murine studies show that
during GVHD, T cells shift from aerobic glycolysis to a com-
bination of glycolysis and OXPHOS [46]. As well, T cells have a
hyperpolarized mt membrane potential and elevated su-
peroxide production. Given these observations and that
mthaps have been associated with time to progression for
multiple sclerosis and human immunodeﬁciency virus
[47,48], various donor mthaps might contribute to aGVHD
(through high OXPHOS) and, perhaps, relapse (through low
OXPHOS). Here, evenwith small numbers, we found patients
of donors with W and U had an increased risk of GVHD. In
further support of immune function effects, mt cybrids have
differential sensitivity to NK cell mediated attack, apparent
in a murine orthotropic tumor model where tumor cybrids
showed differential growth rates based on natural killer cell
recognition [4]. Moreover, it is also possible that the genetic
differences between donor and recipient mtDNA may serve
as a minor histocompatibility antigen, leading to T cell
recognition and increased aGVHD. We were unable to
examine this question, as among our URD and UCB recipient-
donor pairs (n¼ 223), only 15 (6.7%) weremthapmatched. In
a previous study, 2 mt proteins (MTAP8 and MTND3) that
have predicted HLA-A2 binding motifs did not increase
GVHD in mismatched donors and recipients [49]. However,
others have shown that peptides derived frommtDNA can be
presented in the context of MHC class I [50]. There is also
evidence from somatic cell nuclear transfer studies in cattle
that mthap incompatibility between oocytes and donor cells
leads to less developmental competence of constructed
embryos [51]. Therefore, variations in donor and recipient
mtDNA serving as minor histocompatibility antigens remaina distinct possibility in the context of HCTand require further
study.
There are several limitations to these preliminary ana-
lyses. We had very small cell sizes for many of the donor
mthaps that show the most promise for favorable HCT out-
comes (K, K2, X). There were many comparisons and it is
possible that our observations (especially among the smaller
mthap groups) were due to chance. The patient group was
heterogeneous with respect to disease, which could inﬂu-
ence observed associations between disease recurrence and
mthap. However, although we adjusted for a number of po-
tential confounders, we found (ad hoc) that restricting our
analysis to only highly signiﬁcant confounders did not
change results. We also were not able to evaluate the non-
sibling recipient and donor groups separately, nor could we
evaluate mismatch of mthap between donor and recipient.
Nevertheless, despite our small patient numbers, we
demonstrated potential differences in HCT outcomes based
on mthap, especially with regard to NRM, GVHD, and DFS.
There is also growing evidence of a biological basis for such
observations. We will be extending this work to the URD
setting in the National Marrow Donor Program and con-
ducting a large study in over 4200 recipients and 4200 do-
nors to validate our ﬁndings. We will also investigate the
relative contribution of mthap of donor compared with
recipient and HCT outcomes after mismatch. Further, we will
be conducting functional studies of the extrememthaps in an
HCT setting.
If validated, it would be feasible to select donor mthaps
associated with less GVHD and/or relapse (eg, J, K2, U) or
avoid use of donormthaps associatedwith adverse outcomes
(eg, I and V). Notably, although we performed Taqman to
genotype individual SNPs for mthap calls, we have been
provided an estimate of w$11.50 per DNA sample to
completely sequence themt genome and analyze formthaps,
with a turnaround time of only weeks (personal communi-
cation, Dr. Kenneth Beckman, Director of the University of
Minnesota Genomics Center). Thus, it would be economically
feasible and expedient to genotype DNA samples on a large
scale housed at donor centers for mthaps. Moreover, with
over 11 million potential donors in the NMDP pool
(www.bethematch.org) andmore than 22.5 million potential
donors available worldwide, it is likely that additional
matching by mthap is feasible.
Nevertheless, donor selection is becoming increasingly
complex, with multiple factors needing to be considered. We
would speculate that there are a relatively small number of
patients with very common HLA types who have many do-
nors. For these patients, or for recipients of UCB, assessment
of donor mtDNA may lead to improved outcomes by select-
ing donors associated with lower rates of GVHD, etc. How-
ever, for the majority of recipients of adult donor
transplantation, we would speculate that there are relatively
few donors (or no donors). For these patients, it is possible
that mtDNA assessment will not guide donor selection per
se, but may lead to changes in supportive care, such as higher
doses (or levels) of immune suppression and/or more
extensive antibiotics prophylaxis. So, although donor selec-
tion may be further complicated, we envision these data
could ultimately improve outcomes.ACKNOWLEDGMENTS
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